UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2015
OCULAR THERAPEUTIX, INC.
(Exact Name of Company as Specified in Charter)
| Delaware | 001-36554 | 20-5560161 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
34 Crosby Drive, Suite 105
Bedford, MA 01730
(Address of Principal Executive Offices) (Zip Code)
Company’s telephone number, including area code: (781) 357-4000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On March 10, 2016, Ocular Therapeutix, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2015. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
| 99.1 | Press Release of Ocular Therapeutix, Inc., dated March 10, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OCULAR THERAPEUTIX, INC. | ||||||
| Date: March 10, 2016 | By: | /s/ W. Bradford Smith | ||||
| W. Bradford Smith Chief Financial Officer | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release of Ocular Therapeutix, Inc., dated March 10, 2016. | |
Exhibit 99.1
Ocular TherapeutixTM Reports Fourth Quarter and Full Year 2015 Financial
Results
PDUFA target action date of July 24, 2016 for the NDA for DEXTENZA™ for the treatment of post-surgical ocular pain; DEXTENZA advancing in late-stage clinical trials in multiple indications
Initiation of Phase 3 clinical program for OTX-TP for the treatment of glaucoma and ocular
hypertension expected in 3Q 2016
Conference Call Today at 8:00 am Eastern Time
BEDFORD, Mass, March 10, 2016 (BUSINESS WIRE): Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the fourth quarter of 2015 and the twelve months ended December 31, 2015.
“With a July 2016 PDUFA date for our lead program and several planned and ongoing late-stage clinical trials across multiple indications, 2016 will be an important year for us in the development of our innovative sustained-release ophthalmic therapies,” said Amar Sawhney, Ph.D., President and Chief Executive Officer. “Our approach is designed to offer patients an alternative to eye drop therapy with the benefit of simple one-time administration. We are now preparing for the potential FDA approval of DEXTENZA for the treatment of ocular pain following ophthalmic surgery, and are continuing to enroll patients in our ongoing Phase 3 trials with DEXTENZA for post-surgical ocular inflammation and pain, as well as allergic conjunctivitis, with the goal of broadening DEXTENZA’s label. We also plan to initiate the first of two planned Phase 3 trials with OTX-TP for the treatment of glaucoma and ocular hypertension later this year.”
Recent Highlights and Anticipated Near-Term Milestones for Key Development Programs
DEXTENZA for the treatment of post-surgical ocular inflammation and pain
| • | In December 2015, a New Drug Application (NDA) was accepted for filing by the U.S. Food and Drug Administration (FDA) for DEXTENZA (sustained release dexamethasone) Intracanalicular Depot for the treatment of post-surgical ocular pain. |
| • | The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of July 24, 2016 for the NDA. |
| • | The data included in the NDA are from one Phase 2 clinical trial and two Phase 3 clinical trials conducted with DEXTENZA for the treatment of post-surgical ocular inflammation and pain. |
| • | If the FDA grants marketing approval for DEXTENZA for the treatment of post-surgical ocular pain on the PDUFA action date, the Company expects to launch this product in early 2017. |
| • | A third Phase 3 clinical trial for DEXTENZA for post-surgical ocular inflammation and pain is currently enrolling with 285 patients out of a planned total of 436 patients enrolled as of March 7, 2016. |
| • | If the Company achieves favorable results in the third Phase 3 trial and subject to approval of the NDA for post-surgical ocular pain by the FDA, the Company intends to submit an NDA supplement for DEXTENZA in the first half of 2017 aiming to broaden its label to include the post-surgical inflammation indication. |
DEXTENZA for the treatment of allergic conjunctivitis
| • | In November 2015, Ocular Therapeutix commenced enrollment in a second Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA for the treatment of allergic conjunctivitis. |
| • | The Company reported topline results of its first Phase 3 allergic conjunctivitis clinical trial in October 2015. The primary endpoint of treatment of ocular itching associated with allergic conjunctivitis was successfully achieved in this trial. |
| • | If the primary efficacy endpoint for ocular itching is met in the second Phase 3 trial and subject to the approval of the NDA submitted for DEXTENZA for the treatment of post-surgical ocular pain, the Company expects to submit an NDA supplement to the FDA for ocular itching associated with allergic conjunctivitis in the fourth quarter of 2016. |
DEXTENZA for the treatment of inflammatory dry eye disease
| • | In December 2015, Ocular Therapeutix reported encouraging topline results from an exploratory Phase 2 clinical trial designed to evaluate a range of objective and subjective measures (signs and symptoms, respectively) for DEXTENZA for the treatment of inflammatory dry eye disease. |
| • | The trial showed a statistically significant difference between the DEXTENZA treatment arm and the placebo arm in the efficacy measure of total corneal staining change from baseline at day 30. |
| • | Supportive efficacy measures of conjunctival staining showed clinically meaningful benefit; improvement in the frequency and severity of symptoms of eye dryness, itchiness, and scratchiness were also seen. |
| • | This trial was designed to optimize the enrollment of patients based on signs. |
| • | The Company plans to meet with the FDA to discuss the Phase 2 results and potential Phase 3 clinical trial designs for dry eye-related indications. |
OTX-TP (sustained release travoprost) for the treatment of glaucoma and ocular hypertension
| • | Ocular Therapeutix recently announced its Phase 3 clinical development strategy for OTX-TP for the treatment of glaucoma and ocular hypertension following a meeting with the FDA in the first quarter of 2016. |
| • | Ocular Therapeutix intends to commence the first of two planned Phase 3 clinical trials in the third quarter of 2016 after holding an End of Phase 2 meeting with the FDA in the second quarter of 2016. |
| • | The Company does not expect a timolol comparator or validation arm will be required in the study design and does not anticipate that eye drops, placebo or active, will be administered in either arm. |
| • | The Company expects that the FDA will require that OTX-TP show a statistically superior reduction of intraocular pressure (IOP), compared to placebo, as a primary efficacy endpoint, as well as clinically meaningful reduction of IOP. |
Fourth Quarter and Full Year 2015 Financial Results
| • | As of December 31, 2015, cash, cash equivalents and marketable securities totaled $105.1 million. Cash used in operating activities was $8.6 million in the fourth quarter of 2015 and $33.7 million for the year ended December 31, 2015. There was $15.6 million in outstanding debt as of December 31, 2015 and no principal payments are due until January 2017. The Company expects that cash, cash equivalents and marketable securities will be sufficient to fund operating expenses, debt service obligations and capital expenditures through the third quarter of 2017. |
| • | Ocular Therapeutix reported a net loss of approximately $10.6 million, or $(0.43) per share, for the quarter ended December 31, 2015, compared to a net loss of $8.0 million, or $(0.37) per share, for the quarter ended December 31, 2014. The fourth quarter 2015 results include $1.3 million in non-cash charges for stock-based compensation compared to $1.0 million in such non-cash charges in the fourth quarter of 2014. The Company reported a net loss of approximately $39.7 million, or $(1.71) per share, for the year ended December 31, 2015, compared to a net loss of $28.7 million, or $(2.69) per share, for the year ended December 31, 2014. The 2015 results include $4.6 million in non-cash charges for stock-based compensation compared to $5.0 million in such non-cash charges in 2014 including a stock grant made in connection with the expansion of the Company’s intellectual property rights. |
| • | Total operating expenses for the three and twelve month periods ended December 31, 2015 were $10.7 million and $39.9 million, respectively, as compared to $8.1 million and $27.9 million for the comparable periods in 2014. Research and development (R&D) expenses for the three and twelve month periods ended December 31, 2015 were $6.9 million |
| and $26.6 million, respectively, compared to $5.1 million and $18.9 million for the comparable periods in 2014. The increases are primarily related to personnel costs and clinical trials of DEXTENZA and OTX-TP product candidates as well as preclinical development of the Company’s anti-VEGF and TKI programs for the treatment of wet age-related macular degeneration and other back of the eye diseases. |
| • | Ocular Therapeutix generated $0.4 million and $1.8 million in revenue during the three month and twelve month periods ended December 31, 2015 from product sales of ReSure® Sealant and from collaborations with corporate partners. |
| • | As of December 31, 2015, there were approximately 24.8 million shares issued and outstanding. |
Conference Call & Webcast Information
Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 8:00 am Eastern Time to discuss the Company’s financial results and provide a general business update.
The live webcast can be accessed by visiting the investor section of the Company’s website at investors.ocutx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 60154048. An archive of the webcast will be available until March 24, 2016 on the company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis, and in Phase 2 clinical development for inflammatory dry eye disease. An NDA for the post-operative ocular pain indication has been accepted for filing by the FDA with a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being conducted for post-operative ocular inflammation and pain. For glaucoma and ocular hypertension, a Phase 2b clinical trial has been completed with OTX-TP (sustained release travoprost) intracanalicular depot, and the first of two OTX-TP Phase 3 clinical trials is expected to be initiated in the third quarter of 2016. Ocular Therapeutix is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the development and regulatory status of the Company’s product candidates, such as the Company’s expectations and plans regarding regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA™ for post-surgical inflammation and pain, DEXTENZA for the treatment of allergic conjunctivitis, DEXTENZA for dry eye disease and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing development of the Company’s sustained release hydrogel depot technology and the advancement of the Company’s other product candidates, the potential utility of any of the Company’s product candidates, the sufficiency of the Company’s cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the timing and costs involved in commercializing ReSure® Sealant, the initiation and conduct of clinical trials, availability of data from clinical trials and expectations for regulatory submissions and approvals, the Company’s scientific approach and general development progress, the availability or commercial potential of the Company’s product candidates, the sufficiency of cash resources and need for additional financing or other actions and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
Contact:
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
bsmith@ocutx.com
or
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Sales and Marketing
scorning@ocutx.com
OCULAR THERATPUETIX, INC.
STATEMENTS OF OPERATIONS and COMPHRENSIVE LOSS
(In thousands, except share and per share data)
| Three Months Ended December 31, |
Year Ended December 31, |
|||||||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||||||
| Revenue: |
||||||||||||||||||||
| Product revenue |
$ | 394 | $ | 193 | $1,354 | $ | 460 | |||||||||||||
| Collaboration revenue |
42 | 312 | 396 | 312 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total revenue: |
436 | 505 | 1,750 | 772 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Operating expenses: |
||||||||||||||||||||
| Cost of product revenue |
92 | 30 | 319 | 91 | ||||||||||||||||
| Research and development |
6,886 | 5,148 | 26,611 | 18,880 | ||||||||||||||||
| Selling and marketing |
1,143 | 658 | 3,852 | 1,982 | ||||||||||||||||
| General and administrative |
2,590 | 2,216 | 9,165 | 6,913 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total operating expenses |
10,711 | 8,052 | 39,947 | 27,866 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Loss from operations |
(10,275 | ) | (7,547 | ) | (38,197 | ) | (27,094 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Other income (expense): |
||||||||||||||||||||
| Interest income |
45 | — | 166 | 7 | ||||||||||||||||
| Interest expense |
(408 | ) | (407 | ) | (1,724 | ) | (1,119 | ) | ||||||||||||
| Other income (expense), net |
1 | — | 7 | (442 | ) | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total other expense, net |
(362 | ) | (407 | ) | (1,551 | ) | (1,554 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net loss |
(10,637 | ) | (7,954 | ) | (39,748 | ) | (28,648 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Accretion of redeemable convertible preferred stock to redemption value |
— | — | — | (11 | ) | |||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net loss attributable to common stockholders |
$ | (10,637 | ) | $ | (7,954 | ) | $ | (39,748 | ) | $ | (28,659 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Net loss per share attributable to common stockholders, basic and diluted |
$ | (0.43 | ) | $ | (0.37 | ) | $ | (1.71 | ) | $ | (2.69 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Weighted average common shares outstanding, basic and diluted |
24,732,847 | 21,289,378 | 23,244,162 | 10,652,865 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Comprehensive loss: |
||||||||||||||||||||
| Net loss |
$ | (10,637 | ) | $ | (7,954 | ) | $ | (39,748 | ) | $ | (28,648 | ) | ||||||||
| Other comprehensive loss: |
||||||||||||||||||||
| Unrealized loss on marketable securities |
(52 | ) | — | (68 | ) | — | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total other comprehensive loss |
(52 | ) | — | (68 | ) | — | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
| Total comprehensive loss |
$ | (10,689 | ) | $ | (7,954 | ) | $ | (39,816 | ) | $ | (28,648 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||||||
OCULAR THERAPEUTIX, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
| December 31, | ||||||||
| 2015 | 2014 | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 30,784 | $ | 37,393 | ||||
| Marketable securities |
74,280 | 37,435 | ||||||
| Accounts receivable |
193 | 329 | ||||||
| Inventory |
134 | 133 | ||||||
| Prepaid expenses and other current assets |
1,592 | 893 | ||||||
|
|
|
|
|
|||||
| Total current assets |
106,983 | 76,183 | ||||||
| Property and equipment, net |
3,095 | 1,782 | ||||||
| Restricted cash |
228 | 228 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 110,306 | $ | 78,193 | ||||
|
|
|
|
|
|||||
| Liabilities and Stockholders’ Equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 1,957 | $ | 1,316 | ||||
| Accrued expenses and deferred rent |
3,379 | 3,016 | ||||||
| Deferred revenue |
42 | 188 | ||||||
| Notes payable, net of discount, current |
— | 1,354 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
5378 | 5,874 | ||||||
| Deferred rent, long-term |
68 | 112 | ||||||
| Notes payable, net of discount, long-term |
15,272 | 13,511 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
20,718 | 19,497 | ||||||
|
|
|
|
|
|||||
| Commitments and contingencies |
||||||||
| Stockholders’ equity: |
||||||||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2015 and 2014; no shares issued or outstanding at December 31, 2015 and 2014 |
— | — | ||||||
| Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2015 and December 31, 2014; 24,750,281 and 21,333,507 shares issued and outstanding at December 31, 2015 and 2014, respectively |
2 | 2 | ||||||
| Additional paid-in capital |
218,830 | 148,122 | ||||||
| Accumulated deficit |
(129,176 | ) | (89,428 | ) | ||||
| Accumulated other comprehensive loss |
(68 | ) | — | |||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
89,588 | 58,696 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 110,306 | $ | 78,193 | ||||
|
|
|
|
|
|||||